Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
Telomeres and Telomerase02:41

Telomeres and Telomerase

In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
Telomeres and Telomerase02:41

Telomeres and Telomerase

In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rac1 GTPase Regulates the SCF<sup>βTrCP</sup>-Mediated Degradation of Claspin and the Cellular Response of Pancreatic Cancer Cells to Gamma Rays.

Cancers·2026
Same author

ARNT2 repression disrupts neuronal identity and promotes glioblastoma growth.

Cell communication and signaling : CCS·2026
Same author

Role of tankyrase scaffolding in the β-catenin destruction complex and WNT signaling.

bioRxiv : the preprint server for biology·2025
Same author

Structural mechanism of DDX39B regulation by human TREX-2 and a related complex in mRNP remodeling.

Nature communications·2025
Same author

PR55α subunit of protein phosphatase 2A supports KRAS<sup>G12D</sup>-driven tumorigenesis that requires YAP activation.

Oncogene·2025
Same author

Contrasting interferon-mediated antiviral responses in human lung adenocarcinoma cells.

Journal of virology·2025

Related Experiment Video

Updated: Jun 4, 2026

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
08:34

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer

Published on: April 13, 2015

Targeting telomerase-expressing cancer cells.

Michel M Ouellette1, Woodring E Wright, Jerry W Shay

  • 1Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, NE, USA.

Journal of Cellular and Molecular Medicine
|February 22, 2011
PubMed
Summary

Telomeres and telomerase are key targets for cancer therapeutics. This review updates on their role in aging, senescence, and promising clinical trials for cancer treatment.

More Related Videos

Generation of Cancer Cell Clones to Visualize Telomeric Repeat-containing RNA TERRA Expressed from a Single Telomere in Living Cells
09:13

Generation of Cancer Cell Clones to Visualize Telomeric Repeat-containing RNA TERRA Expressed from a Single Telomere in Living Cells

Published on: January 17, 2019

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Experiment Videos

Last Updated: Jun 4, 2026

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
08:34

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer

Published on: April 13, 2015

Generation of Cancer Cell Clones to Visualize Telomeric Repeat-containing RNA TERRA Expressed from a Single Telomere in Living Cells
09:13

Generation of Cancer Cell Clones to Visualize Telomeric Repeat-containing RNA TERRA Expressed from a Single Telomere in Living Cells

Published on: January 17, 2019

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Area of Science:

  • Oncology
  • Molecular Biology
  • Gerontology

Background:

  • Telomeres and telomerase are crucial in cellular aging and cancer development.
  • Replicative senescence acts as a barrier against cancer cell immortalization.
  • Dysfunctional telomeres are linked to aging and cancer progression.

Purpose of the Study:

  • To provide an update on telomeres and telomerase as cancer therapeutic targets.
  • To identify knowledge gaps and promising clinical advancements.
  • To explore selective targeting strategies for enhanced cancer therapy.

Main Methods:

  • Review of current literature on telomere and telomerase biology.
  • Analysis of emerging therapeutic strategies in clinical trials.
  • Discussion of immunotherapy, gene therapy, and oligonucleotide-based approaches.

Main Results:

  • Dysfunctional telomeres contribute to cellular aging and senescence.
  • Targeting telomeres and telomerase offers potential for cancer treatment.
  • Several promising therapeutic strategies are advancing into clinical trials.

Conclusions:

  • Telomere and telomerase research continues to be vital for cancer therapeutics.
  • Selective targeting strategies show promise for enhancing cancer therapy efficacy.
  • Further research is needed to address knowledge gaps and optimize treatment outcomes.